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Cortactin is an actin-binding Src substrate involved in cell motility and invasion. In this study, we sought to examine the prognostic
importance of cortactin protein expression in head and neck squamous cell carcinoma (HNSCC). To do so, cortactin and EGF
receptor (EGFR) expression was retrospectively evaluated by immunohistochemistry in a tissue microarray composed of 176
HNSCCs with a mean follow-up time of 5 years. Cortactin immunoreactivity was weak to absent in normal epithelial tissue.
Overexpression of the protein in 77 out of 176 tumours (44%) was associated with more advanced tumour-node-metastasis stage
and higher histologic grade. Cortactin overexpression was associated with significantly increased local recurrence rates (49 vs 28% for
high and low expressing carcinomas, respectively), decreased disease-free survival (17 vs 61%), and decreased the 5-year overall
survival of (21 vs 58%), independently of the EGFR status. In multivariate analysis, cortactin expression status remained an
independent prognostic factor for local recurrence, disease-free survival, and overall survival. Importantly, we identified a subset of
patients with cortactin-overexpressing tumours that displayed low EGFR levels and a survival rate that equalled that of patients with
tumoral overexpression of both EGFR and cortactin. These findings identify cortactin as a relevant prognostic marker and may have
implications for targeted therapies in patients with HNSCC.
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Despite recent advances in cancer treatment, the 5-year overall
survival rate for patients with squamous cell carcinoma of the head
and neck (HNSCC) has not improved over the last 30 years
(Forastiere et al, 2001; Greenlee et al, 2001). The primary cause of
treatment failure in patients with early-stage disease is the
development of second primary tumours, whereas patients who
present with locally advanced disease are at risk for local–regional
recurrence and metastasis, even with the use of near-tolerance
doses of radiation (Day and Blot, 1992). Most of the current
prognosis factors (such as tumour-node-metastasis (TNM) staging,
surgical margin status, and perineural invasion) fail to provide
definitive information regarding the biological behaviour of the
tumour and its potential to recur. Thus, identifying a biological
marker that correlates with recurrence would provide more
accurate information on prognosis and enable the treating
physician to select a more aggressive course of therapy for high-
risk patients. Such a marker could also potentially serve as a target
for drugs designed to seek out and exploit specific molecular
defects in cancerous cells.
Tumour cell motility is required for local–regional invasion and
metastasis. Motility is initiated by protrusion of the leading edge of
the cell, resulting in the production of polarised lamellipodia
oriented towards the direction of movement (Yamaguchi and
Condeelis, 2007). Cortactin is a ubiquitously expressed Src
substrate that engages in several protein–protein interactions that
may be functionally relevant to tumoral progression. It accumu-
lates in lamellipodia of motile cells where it plays a crucial role in
the dynamic regulation of the actin cytoskeleton by virtue of its
binding to filamentous (F) actin, Arp2/3, and components of the
cortical actin-polymerising machinery (Weed and Parsons, 2001;
Daly, 2004). Cortactin also colocalises with F-actin in invadopodia
of metastatic tumour cells, where it participates in degradation of
the extracellular matrix around tumours (Artym et al, 2006;
Yamaguchi et al, 2006). The cortactin gene CTTN (formerly EMS1)
resides on chromosome locus 11q13 that is frequently amplified in
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shuman cancers, including over 30% HNSCCs (Brookes et al, 1993;
Schuuring, 1995; Huang et al, 2006; Gibcus et al, 2007). Thus, the
functional properties of cortactin, together with amplification of
chromosome locus 11q13, suggest a link between its overexpres-
sion and tumour invasion and/or metastasis. Accordingly, in
several animal models ectopic overexpression of cortactin has been
shown to accelerate tumour dissemination, and decreased expres-
sion of cortactin, by RNA interference, leads to impaired tumour
cell migration and metastasis (Li et al, 2001; Chuma et al, 2004;
Hill et al, 2006; Luo et al, 2006).
A growing list of cortactin-binding partners has been identified,
including proteins that regulate receptor clustering, endocytosis, and
vesicle transport such as dynamin 2 (McNiven et al, 2000) and
CD2AP (CIN85-related protein) (Lynch et al, 2003). Recent results
from studies in cultured cells (Lynch et al, 2003; Timpson et al, 2005)
indicate that cortactin could participate in receptor-mediated
endocytosis of the epidermal growth factor (EGF) receptor (EGFR).
Thus, cortactin overexpression attenuated ligand-induced down-
regulation of EGFR and led to sustained activation of EGFR
signalling. Conversely, reduction of cortactin expression in an
11q13-amplified HNSCC cell line by RNA interference accelerated
EGFR degradation (Timpson et al,2 0 0 5 ) .O nt h eb a s i so ft h e s e
findings, it was proposed that overexpression of cortactin may
contribute to increased EGFR expression and signalling in
malignancies with CTTN amplification. This is of particular
importance in HNSCC, since enhanced EGFR signalling/expression
has been associated with aggressive disease and poor prognosis
(Dassonville et al, 1993; Grandis and Tweardy, 1993; Kalyankrishna
and Grandis, 2006) and EGFR-targeted molecular therapeutics are
currently being examined in clinical settings (for recent reviews, see
Astsaturov et al, 2006a, 2006b and Reuter et al, 2007).
To determine whether cortactin expression could be an
independent prognostic factor in HNSCC, we have investigated
expression of the protein in a large series of HNSCCs using tissue
microarray (TMA) technology and have correlated this expression
to the outcome of these patients. Epidermal growth factor receptor
staining was performed to investigate the potential linkage
between cortactin and EGFR overexpression.
MATERIALS AND METHODS
Patient selection
Surgically removed tumours embedded in paraffin wax blocks
from 176 cases of HNSCCs were retrieved from the archives of the
Department of Pathology (Pasteur Hospital) at the University of
Nice, Nice, France. The cases, received between 1993 and 2001,
included squamous cell carcinomas exclusively from patients
without metastases; basaloid type carcinoma and other nonmuco-
sal tumours were excluded. Cases were selected to build TMAs and
included in this study only if a follow-up of at least 5 years was
obtained, and clinical data were available. Mean age at surgery was
63 years (range: 37–82) and 138 patients were male. Selected
patients displayed similar health status and absence of concurrent
chronic illnesses, or tumours elsewhere. The primary sites of the
carcinomas were oral cavity (n¼40), pharynx (n¼57; including
oropharynx, n¼31 and hypopharynx, n¼26), and larynx (n¼79).
Tumour size according to the TNM classification was T1 (n¼34),
T2 (n¼44), T3 (n¼48), and T4 (n¼50). Eighty-seven per cent of
the carcinomas were keratinising, with a range of grades: grade I
(n¼27), grade II (n¼94), and grade III (n¼55).
Tissue microarray construction
Tissue microarray construction and high-throughput analysis of
tissue samples were performed in accordance with Institutional
Guidelines. Haematoxylin and eosin-stained sections of primary
tumours were reviewed, and areas of tumour and normal tissue
were marked on the slides. Areas of necrosis and keratin pools were
avoided. Representative carcinoma areas were selected for building
TMAs and arrays were designed as previously described (Hoos and
Cordon-Cardo, 2001). Briefly, three tissue cores (600mmi n
diameter) corresponding to three representative central areas of
the tumour were selected. The tissue cores were arrayed into a
recipient paraffin block using a fine steel needle and an automatic
tissue microarrayer (Beecher Instruments, Sun Prairie, WI, USA
and Alphelys, Paris, France). Tissue microarrays of primary
carcinomas contained normal tissue adjacent to benign oral
tumours from patients (six tissue cores from biopsies performed
on these patients), who served as control and for regulating mark
spacing between core centres; cores were spaced at intervals of
1mminthex and y axes. A 4-mm haematoxylin- and eosin-stained
section was reviewed to confirm the presence in TMAs of
morphologically representative areas of the original lesions.
Immunohistochemistry
Immunohistochemical methods were performed on serial 2mm
deparaffinized TMA sections. For cortactin detection, intrinsic
peroxidase was blocked by incubating sections with 3% hydrogen
peroxide for 6min. Sections were blocked in 4% goat serum for
20min, then incubated for 30min with mouse monoclonal antic-
ortactin antibody (clone 4F11; Upstate, Lake Placid, NY, USA and
Euromedex, Souffelweyersheim, France). After rinsing with PBS,
sections were incubated with biotinylated secondary antibody for
20min, rinsed with PBS, and incubated with anti-mouse Ig’s
streptavidin complexed with biotinylated peroxidase (StreptAB-
Complex/HRP; DAKO Corp., Carpinteria, CA, USA) for 20min.
Sections were then washed with distilled water, incubated with
developing solution (3-amino-9-ethylcarbazole; DAKO), counter-
stained with haematoxylin, and mounted with aqueous mounting
medium. Epidermal growth factor receptor was detected on
sequential sections using the Invitrogen immunodetection kit
(mouse anti-EGFR clone 31G7), as indicated by the manufacturer.
After staining, slides were analysed with an image-analysis work-
station (Spot Browser version 7; Alphelys), as previously described
(Pages et al, 2005). Signal intensity of digitised images was
determined using the Spot Browser software; grey values (0¼black
to 255¼white) ranged between 102 and 142, and a value inferior or
equal to 120 was defined as overexpression. In parallel, staining of
the cores was scored by pathologists based on signal intensity
(0–3) and the percentage of positive cells (0p10%, 1¼10–25%,
2¼25–50%, and 3X50%). Overexpression of cortactin and EGFR
was arbitrarily defined as more than 50% of cells strongly (score 3)
stained. Input from visual inspection data and detection of events
in digitised images was stored in dedicated tables for comparison
and statistical analysis. Discrepancies were resolved by three
pathologists (CB, VH, and PH) using a multihead microscope.
A disc was considered unsuitable for analysis if it was completely
absent, it contained no tumour tissue (sampling error), or it
contained too few tumour cells (o10%) for analysis (uninforma-
tive). For each patient, the mean score of a minimum of two core
biopsies was calculated. Whole-tissue sections from tumour blocks
of a subset of 30 cases were stained and compared by visual
inspection with the corresponding TMA discs using the above-
mentioned scoring criteria. These cases were selected to include 10
cases of each grade, and clinicopathological data of these cases were
very similar to those of the whole series (not shown). Negative
controls for staining used in this study were normal oral mucosa
for cortactin and normal striated muscle for EGFR.
For figures, polychromatic high-resolution spot images
(1392 1040 pixels) were obtained using a Leica DMR optic
microscope (Leica Microsystems, Rueil-Malmaison, France)
equipped with a CoolSNAP EZ cooled charge-coupled device
camera (Roper Scientifique, Evry, France).
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Histospots containing o10% of a tumour were excluded from
additional analyses. Disease-free survival, overall survival, and
local recurrence were assessed by Kaplan–Meier analysis with log-
rank score for determining statistical significance. All survival
analyses were performed at 5-year cutoffs. Relative risk was
assessed by the univariate and multivariate Cox proportional
hazards model. Comparison of cortactin overexpression with the
clinical and pathological variables including gender, TNM stage,
histological grade, and tumour type (primary vs recurrent) was
made using w
2 analysis. Calculations and analyses were performed
with SPSS 11.5 for Windows (SPSS Inc., Chicago, IL, USA) and
where appropriate, were two tailed.
Nonparametric correlation (Spearman’s r coefficient; SPSS
release 12.01) was used to compare data from whole-tissue
sections and discs; and to relate the mean scores obtained from
four discs to the scores obtained from individual discs, the mean
scores of two discs, and the mean scores for three discs. The degree
of agreement between data from whole-tissue sections and the
mean of four discs was assessed using weighted Cohen’s
k coefficient (SAS for Windows, release 8.02). For descriptive
purposes, ko0.4 represents poor-to-fair agreement, 0.4–0.6
moderate agreement.
RESULTS
Clinical and pathological variable analysis
One hundred and seventy-six patients who underwent primary
surgical resection for HNSCC in the Department of Otorhino-
laryngology (CHU of Nice, France) met inclusion criteria to build
TMAs. Demographic and clinicopathological variables for the
cohort are summarised in Table 1.
Immunohistochemical analysis of cortactin and EGFR
expression
Cortactin immunoreactivity in normal epithelial tissue was low to
undetectable (Figure 1A–B). Staining was observed in blood
vessels of the underlying connective tissue, both in capillary
endothelial cells and in a-actin-positive smooth muscle cells of
larger vessels. Interestingly, the presence of cortactin in endothelial
cells and in perivascular cells was often mutually excusive (data
not shown). Epidermal growth factor receptor staining in normal
epithelium was intense in the basal and suprabasal proliferative
layers and undetectable in the connective tissue and blood vessels
(not shown).
Of the HNSCC tumours that met inclusion criteria, all were
interpretable for cortactin staining. Tumours displayed one of the
three distinct immunostaining phenotypes (Figure 1): intense
diffuse membranous and/or cytoplasmic staining (Figure 1C–D),
weak cytoplasmic and/or membranous staining (Figure 1E), and
absence of staining (Figure 1F). Cortactin overexpression was
defined as intense diffuse cytoplasmic and/or plasma membrane
staining in 450% of tumour cells. In all, 77 out of 176 tumours
were designated as cortactin overexpressors. No staining was
observed in any spots stained with the negative control reagent.
Comparisons were made between clinical/pathological variables
and cortactin status by w
2 analysis. Cortactin overexpression was
significantly associated with higher TNM stage (P¼0.005), as 38
out of the 77 cortactin-overexpressing tumours (49%) were stage
IV, as compared with 50 out of the total 176 tumours analysed
(28%). Cortactin overexpression was also associated with higher
histologic grade as 44 out of 77 cortactin-overexpressing tumours
were poorly differentiated (P¼0.001). There was no association
between cortactin status and the other clinical/pathological
variables indicated in Table 1. In particular, no association
between cortactin status and primary tumour site (oral cavity,
oropharynx or hypopharynx, and larynx) was noted.
Epidermal growth factor receptor overexpression is known to be
associated with advanced TNM stage, higher histologic grade, and
recurrent head and neck tumours (see Dei Tos and Ellis, 2005).
This was confirmed for the present cohort by analysis of EGFR
expression, as summarised in Table 1. To examine the possible
association between the pattern of EGFR expression and cortactin
status, a pairwise analysis was performed. Interestingly, none of
the tumour specimens with low cortactin levels (cortactin
nonoverexpressors) overexpressed the EGFR. Tumours that over-
express cortactin were largely positive for EGFR (Figure 2A–B).
However, in our series we identified a group of 29 tumours with
intense cortactin expression in which the EGFR was not over-
expressed (Figure 2C–D). These include 10 T1, 9 T2, and 9 T3 (all
N0M0) tumours. Ten of these tumours were well differentiated and
19 tumours were moderately or poorly differentiated.
Importantly, cortactin and EGFR expression levels observed in
the TMA discs faithfully reflected the staining intensity of these
proteins in whole-tissue sections from corresponding tumour
blocks in a subset of 30 cases (see Materials and Methods section).
Survival analysis
Local recurrence The expression status of cortactin, as deter-
mined by immunohistochemistry, was evaluated for association
with local recurrence using Kaplan–Meier survival analysis with
log-rank statistics for determining significance. This analysis
Table 1 Comparison of cortactin and EGFR status to demographic,
clinical, and pathologic data
Cortactin status
a EGFR status
a
n   + Pn   + P
Patient cohort
Age (years) 37–82 (median 63)
Interpretable for cortactin 176 99 77
Interpretable for EGFR 176 66 110
Positive control
Interpretable for cortactin 7 0 7
Noninterpretable 1
Interpretable for EGFR 9 2 7
Noninterpretable 2
Gender
Male 138 76 62 0.11 138 36 102 0.13
Female 38 23 15 38 30 8
Site
Oral cavity 40 20 20 0.42 40 10 30 0.39
Pharynx 57 42 15 57 21 36 0.11
Larynx 79 66 13 79 35 39
TNM stage
I 34 15 19 0.005
w 34 24 10 0.004
w
II 44 19 25 44 20 24
III 48 15 23 48 16 32
IV 50 12 38 50 14 36
Grade
Well differentiated 27 15 12 0.001
w 27 16 11 0.001
w
Moderately differentiated 94 24 70 94 34 60
Poorly differentiated 55 11 44 55 11 44
EGFR¼epidermal growth factor receptor; TNM¼tumour node metastasis.
aCortactin/EGFR status: ( )¼nonoverexpressor; (+)¼overexpressor. wSignificant
at the 0.01 level.
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sdemonstrated that cortactin overexpression is associated with
increased local recurrence rates. Patients with cortactin nonover-
expression have a local recurrence rate of 28%, compared with
49% for cortactin-overexpressing patients (Figure 3A). Among
these latter patients with cortactin-overexpressing tumours, no
differences relating to the initial treatment (postoperative radio-
therapy alone or not, and postoperative chemotherapy plus
radiotherapy or not) were noted. Univariate Cox analysis revealed
a hazard ratio for cortactin overexpressors of 6.0 (P¼0.014).
Disease-free survival
Kaplan–Meier survival analysis (Figure 3B) demonstrated that
cortactin overexpression is associated with decreased disease-free
survival. Patients with cortactin nonoverexpression have a 5-year
disease-free survival of 61%, compared with 17% for cortactin
overexpression (P¼0.0040). Univariate Cox analysis revealed a
hazard ratio for cortactin-overexpressing patients of 2.6
(P¼0.007).
Overall survival
Kaplan–Meier survival analysis (Figure 3C) demonstrated that
cortactin overexpression is associated with decreased overall
survival. Patients without cortactin overexpression had a 5-year
overall survival of 58%, compared with 21% for cortactin
overexpression (P¼0.0170). Univariate Cox analysis revealed a
hazard ratio for cortactin-overexpressing patients of 2.3
(P¼0.024).
Figure 1 Cortactin expression in normal oral mucosa and HNSCC. Staining of cortactin was performed as indicated in Materials and Methods. Normal
epithelium (A–B) is devoid of staining, arrowheads indicate cortactin staining of blood vessels. Scale bar represents 200mm in the tissue core shown in
panel A and 100mm in the higher magnification images shown in panels B–F. (C–D) Squamous cell carcinoma demonstrating strong membrane and
cytoplasmic staining, respectively. (E) Squamous cell carcinoma exhibiting weak staining. (F) Squamous cell carcinoma displaying absence of
immunohistochemical staining. Only strong staining (C–D) was scored as cortactin overexpression. Weak staining or absence of staining (E–F) was
scored as negative for this study. Calibration bar represents 200mm in images on the left.
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sFigure 2 Epidermal growth factor receptor and cortactin expression in HNSCC. Squamous cell carcinoma demonstrating both strong cortactin (A) and
EGFR (B) coexpression. Squamous cell carcinoma demonstrating cortactin overexpression (C) and EGFR nonoverexpression (D). (Scale bar¼200mm).
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Figure 3 Kaplan–Meier estimates of the 5-year local recurrence (A), disease-free survival (B), and overall survival (C), by cortactin status. Cortactin
overexpressors had significantly lower disease-free and lower survival rates than nonoverexpressors. Additionally, cortactin overexpressors had higher local
recurrence rates than nonoverexpressors. Kaplan–Meier estimates of the 5-year overall survival by both EGFR and cortactin status (D).
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disease-free survival, and overall survival are summarised in
Table 2. In parallel, the expression status of EGFR was evaluated
for association with overall survival. As mentioned above, EGFR
overexpression is associated with decreased overall survival.
Results for univariate survival analysis of local recurrence,
disease-free survival, and overall survival for this cohort are
summarised in Table 3. Interestingly, patients with tumours that
do not overexpress the EGFR but overexpress cortactin had a
5-year overall survival of 22%, similar to patients with tumours
that overexpress both EGFR and cortactin (Figure 3D).
Multivariate analysis
Using the Cox proportional hazards model, we performed multi-
variate analysis to assess the independent predictive value of
cortactin expression for 5-year disease-free survival, overall
survival, and local recurrence. The following prognostic variables
were also included tumour type (primary vs recurrent), TNM
stage, and histologic grade. For disease-free survival, only cortactin
expression status remained an independent prognostic factor
(P¼0.01). For overall survival, both cortactin status and TNM
stage were independent prognostic factors (P¼0.038 and 0.014,
respectively). The results for the multivariate survival analysis are
summarised in Table 2. Similarly, for overall survival both EGFR
status and TNM stage were independent prognostic factors
(P¼0.041 and 0.011, respectively). The results for the multivariate
survival analysis for EGFR are summarised in Table 3.
DISCUSSION
Amplification of the CTTN gene has been linked to poor prognosis
in HNSCC (Rodrigo et al, 2000), yet the relationship between
cortactin protein levels and prognosis has not been thoroughly
investigated to date. Tissue microarrays have previously been
shown to represent reliable tools for the identification of cellular
and molecular alterations in several tumour types, including
HNSCCs (Gomaa et al, 2005). Recently, in a small number of
HNSCCs, 11 out of 39 (28%) cases, cortactin overexpression
determined by immunohistochemistry correlated with lymph node
metastasis and CTTN gene amplification (Rothschild et al, 2006).
In the present study of 176 tumours, we found by quantitative
immunohistochemical analysis of TMAs, that cortactin expression
status in the tumours of patients with HNSCC is a strong
independent prognostic factor for local recurrence as well as
disease-free and overall survival. Hence, patients with cortactin-
overexpressing tumours displayed a five-fold increase in the risk of
local recurrence and nearly a three-fold increase in risk of death by
any cause. Importantly, cortactin expression status remained an
independent prognostic factor in multivariate analysis.
Several gain- and loss-of-function studies over the past few years
have convincingly demonstrated the role of cortactin in regulation
Table 2 Univariate and multivariate Cox regression analyses by cortactin expression levels
Cortactin status
Mean time to recurrence
(months)
Percentage of recurrence (95% confidence
interval)
Hazard ratio (95% confidence
interval) P
Univariate
Local recurrence
Overexpressor 32.0 49.1% (39–66) 6.032 (1.6–27.1) 0.014
Nonoverexpressor 47.0 28.0% (16–49) 0.169 (0.05–0.8)
Disease-free survival
Overexpressor 22.2 61.5% (40–81) 2.586 (1.2–5.9) 0.007
Nonoverexpressor 34.7 17.5% (11–29) 0.379 (0.3–0.8)
Overall survival
Overexpressor 29.2 57.8% (35–80) 2.275 (1.2–4.7) 0.024
Nonoverexpressor 42.5 20.9% (11–30) 0.425 (0.3–0.9)
Multivariate
Variable Hazard ratio 95% confidence interval P
Local recurrence
Tumour type 1.675 0.8–3.7 — 0.20
TNM stage 1.412 0.8–2.4 — 0.20
Histologic grade 0.965 0.6–1.6 — 0.90
Cortactin
overexpressor
5.293 1.2–23.6 — 0.029*
Disease-free survival
Tumour type 1.616 0.9–3.0 — 0.13
TNM stage 1.453 1.0–2.1 — 0.06
Histologic grade 1.033 0.7–1.5 — 0.87
Cortactin
overexpressor
3.000 1.3–7.0 — 0.010*
Overall survival
Tumour type 1.648 0.9–3.1 — 0.12
TNM stage 1.679 1.1–2.5 — 0.014*
Histologic grade 0.984 0.7–1.5 — 0.94
Cortactin
overexpressor
2.449 1.1–5.7 — 0.038*
TNM¼tumour node metastasis. *Significant at the 0.05 level.
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remodelling, invadopodia formation, adhesion, endocytosis, and
regulation of cell–cell junctions (reviewed in Daly, 2004).
Although the acquisition of a motile phenotype has conventionally
been regarded as a late event in tumour progression, it was
recently proposed that aberrant cell motility may, in addition to
being essential to tumour invasion and metastatic dissemination,
also contributes significantly to rapid tumour growth (Norton and
Massague, 2006). Indeed, cortactin overexpression in our study
was associated advanced TNM stage and high histologic grade.
From the pathologist’s point of view, cortactin overexpression
could be a new prognosis marker for HNSCC.
Cortactin is a substrate of c-Src, and activation of Src family
tyrosine kinases is known to be critically involved in carcinoma
cell migration extracellular matrix degradation and invasive
behaviour. In HNSCC cells, c-Src was proposed to be a down-
stream target of the EGFR, as treatment of cells with the EGFR
inhibitor ZD1839 was found to block activation of the c-Src
pathway (Yang et al, 2004). Src family kinases were also shown to
be involved in mediating activation of STATs 3 and 5 in concert
with the EGFR in HNSCC cells (Xi et al, 2003). This evidence for a
functional association between EGFR and Src/cortactin pathways
prompted us to examine EGFR levels in our TMAs. In the majority
of cases, EGFR overexpression mirrored cortactin overexpression.
However, we identified a subset of 29 tumours in which cortactin
and EGFR overexpression could be uncoupled. In these tumours,
intense cortactin staining occurred in the absence of strong
EGFR staining. Interestingly, patients harbouring these tumours
displayed a 5-year overall survival rate that was similar to that of
patients with tumours that overexpress both EGFR and cortactin
(22 vs 19%, respectively). This finding was unexpected in light of
recent studies by Timpson et al (2005) suggesting that cortactin
overexpression may contribute to EGFR overexpression. In
cultured cells, cortactin overexpression inhibited ligand-induced
downregulation of the EGFR (Timpson et al, 2005). Although
elevated EGFR expression in tumours is usually associated with
more aggressive disease and poor clinical prognosis; in some
studies EGFR expression was found to have no prognostic
significance (see Dei Tos and Ellis, 2005). This may be the case
for the subset of cortactin-overexpressing/EGFR-nonoverexpres-
sing tumours that we describe in which activation or over-
expression of signalling components downstream of the receptor
could influence cell survival and growth. Whereas these patients
may not benefit from EGFR-targeting strategies, they could
respond to alternate inhibitors such as Src family kinases that
are currently undergoing phase I/II evaluations in advanced solid
tumours.
Therapies that target the EGFR have generated high hopes for
the management of head and neck cancer. Several clinical trials
that explore the use of agents directed against the EGFR, alone or
together with various combinations of radiation and chemotherapy,
and are currently underway. However, as witnessed in various
tumour settings, use of such agents is not without undesirable
consequences, and treatment can lead to toxicity and acquired
drug resistance. Recently, expression of a tumour-specific
constitutively active spliced variant of the receptor (EGFRvIII)
Table 3 Univariate and multivariate Cox regression analyses by EGFR expression levels
EGFR status Mean time to recurrence (months)
Percentage of recurrence
(95% confidence interval)
Hazard ratio
(95% confidence interval) P
Univariate
Local recurrence
Overexpressor 35.0 48.1% (38–64) 6.112 (1.3–22.1) 0.011
Nonoverexpressor 49.0 34.0% (30–46) 0.135 (0.03–0.5)
Disease-free survival
Overexpressor 24.2 59.2% (40–79) 2.786 (1.3–5.8) 0.005
Nonoverexpressor 36.7 16% (11–29) 0.323 (0.3–0.6)
Overall survival
Overexpressor 26.2 55.5% (34–79) 2.550 (1.2–4.7) 0.023
Nonoverexpressor 39.5 19.8% (14–30) 0.398 (0.2–0.8)
Multivariate
Variable Hazard ratio 95% confidence interval P
Local recurrence
Tumour type 1.556 0.7–3.5 — 0.25
TNM stage 1.398 0.7–2.6 — 0.25
Histologic grade 0.889 0.5–1.3 — 0.80
EGFR overexpressor 5.377 1.1–20.5 — 0.025*
Disease-free survival
Tumour type 1.557 0.8–2.8 — 0.11
TNM stage 1.559 1.1–2.5 — 0.08
Histologic grade 1.110 0.9–1.9 — 0.79
EGFR overexpressor 2.599 1.2–6.1 — 0.012*
Overall survival
Tumour type 1.559 0.8–3.5 — 0.15
TNM stage 1.450 1.3–2.7 — 0.011*
Histologic grade 0.999 0.9–1.8 — 0.84
EGFR overexpressor 2.568 1.2–5.9 — 0.041*
EGFR¼epidermal growth factor receptor; TNM¼tumour node metastasis. *Significant at the 0.05 level.
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swas detected in 44% of a small cohort of HNSCCs and found to
contribute to enhanced growth and resistance to wild-type EGFR-
targeting antibodies (Sok et al, 2006). Altogether these events
highlight the therapeutic advantage that targeting multiple
components of the EGFR/Src/cortactin axis could represent.
Interestingly, recent studies in mammary tumour cells by
Hashimoto et al (2006) illustrate the role of cortactin itself as a
potential therapeutic target. Thus, blocking the interaction of the
cortactin SH3 domain with AMAP1 (a GTP-Arf6 effector over-
expressed in invasive mammary tumours) with a cell-permeable
peptide derived from the AMAP1 sequence, or a small-molecule
compound, was found to effectively inhibit AMAP1/cortactin
binding, and breast cancer invasion and metastasis (Hashimoto
et al, 2006).
Numerous investigations have addressed genomic alterations
that accompany HNSCC using various techniques (e.g., compara-
tive genomic hybridisation, DNA microarrays, and fluorescence in
situ hybridisation). Amplification of the 11q13 locus, where CTTN
resides, is the most frequent amplification event in HNSCC and
may be driven by a set of genes that could cooperatively provide
growth or metastatic advantage to cancer cells including CCND1,
FGF4, FGF3, SHANK2, and PAK1 (see Huang et al, 2002, 2006 and
Gibcus et al, 2007). Indeed, recurrent coamplification of the
cytoskeleton-associated genes CCTN and SHANK2 with the cell-
cycle control gene CCND1 has been observed in oral squamous cell
carcinoma (Freier et al, 2006). Future studies are warranted to
determine the possible involvement of other gene products of the
11q13 amplicon in HNSCC. For example, both activity and
expression of the serine/threonine kinase Pak1, an effector of the
Rac and Cdc42 GTPases and potential cortactin accomplice, was
found to be elevated in head and neck tumours as compared with
adjacent normal tissue biopsy specimens (Yang et al, 2004),
although this study was limited to a small number of tumours.
In conclusion, high levels of cortactin protein expression in
HNSCC were closely associated with poor prognosis. Although the
precise mechanism remains to be elucidated, this finding is
important for several reasons. First, it identifies cortactin as a
strong, independent prognostic indicator in patients with HNSCC.
Second, it identifies the Src substrate, cortactin as a relevant
prognostic marker and pertinent molecular target for development
of new antitumoral agents and raises the possibility that cortactin
status may guide clinicians in tailoring future therapy.
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